Biocon entered into an exclusive licensing and supply agreement with Biomm SA of Brazil, enabling Biomm to commercialize Biocon’s drug Semaglutide (marketed as ozempic) for the management of type 2 diabetes in adults. Biocon will handle the development, manufacturing, and supply of the drug products, while Biomm will take charge of securing regulatory approval and overseeing commercialization in the Brazilian market.
Biomm specializes in providing healthcare solutions to patients with chronic conditions, leveraging cutting-edge technologies and treatments. The company’s focus lies in the development, manufacturing, and commercialization of complex biotech and biosimilar drug products at its production facility located in Nova Lima.
As reported by Business Standard, Biomm informed that Brazil ranks fifth globally in terms of diabetes prevalence, with 16.8 million adults aged 20 to 79 affected by the disease. The company also noted projections from the International Diabetes Federation Diabetes Atlas indicating that this number is expected to increase to 21.5 million by the year 2030.
